Condition: Duchenne Muscular Dystrophy (DMD) · Muscular Dystrophy, Duchenne · Muscular Dystrophy (DMD) · Sponsor: Dyne Therapeutics
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
This description comes directly from the study's public registry record.
Dyne Clinical Trials · +1-781-317-1919 · clinicaltrials@dyne-tx.com
Always discuss trial participation with your own doctor first.
| Rare Disease Research, LLC | Hillsborough, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07608432